On January 20, Changchun High And New Technology Industries (Group) Inc(000661) fell to the limit at the opening!
On January 19, Changchun High And New Technology Industries (Group) Inc(000661) suddenly collapsed and fell to the limit, reporting 227.6 yuan / share. Since December 17, 2021, Changchun High And New Technology Industries (Group) Inc(000661) share price has been in a negative decline mode.
Changchun High And New Technology Industries (Group) Inc(000661) continuous decline, “medicine goddess” Glen was deeply set again! Its management of China Europe medical and health is Changchun High And New Technology Industries (Group) Inc(000661) the fifth largest circulating shareholder. In the past month, the two pharmaceutical funds managed by Glenn fell by 10.47% and 11.32% respectively, and both fell by more than 20% in the past three months.
Gran, the “goddess of medicine”, also planted
On January 19, Guangdong Pharmaceutical Trading Center issued the document on centralized procurement of diclofenac and other drugs of Guangdong alliance, and published 276 drug procurement lists, of which the recombinant human growth hormone of Changchun High And New Technology Industries (Group) Inc(000661) subsidiary kinsay pharmaceutical was included in the centralized procurement.
Changchun High And New Technology Industries (Group) Inc(000661) responded on the investor interaction platform after trading that day: the company is currently actively studying policies and regulations and will formulate reasonable plans. At present, there is no expectation of specific impact.
Affected by this, Changchun High And New Technology Industries (Group) Inc(000661) has dropped the limit for two consecutive days. Since December 17, 2021, Changchun High And New Technology Industries (Group) Inc(000661) share price has always been in a negative decline mode. As of the noon closing on January 20, Changchun High And New Technology Industries (Group) Inc(000661) reported 204.84 yuan / share, down 60.8% from the historical high of 522.17 yuan / share, and the total market value also fell below the 100 billion yuan mark, with the latest report of 92.1 billion yuan.
Changchun High And New Technology Industries (Group) Inc(000661) has fallen for a month in a row, and the “goddess of medicine” Gran has been deeply trapped again.
According to wind data, as of November 23, 2021, the China EU medical and health mixed fund managed by Glenn held Changchun High And New Technology Industries (Group) Inc(000661) 5517200 shares, ranking the fifth largest circulating shareholder.
Since the second quarter of 2020, Glenn has continued to increase its position Changchun High And New Technology Industries (Group) Inc(000661) . However, there was a position reduction in the third quarter of 2021. It is worth noting that from the end of the third quarter of 2021 to November 23, 2021, Glenn increased its position again. Compared with 5099200 shares at the end of the third quarter, Glenn increased its position by 418000 shares in the fourth quarter.
In addition to Ge Lan, two funds managed by e fund Zhang Qinghua, e fund Yufeng Return Bond Fund and e fund new income flexible allocation hybrid fund, also appeared in the list of the top ten circulating shareholders of Changchun High And New Technology Industries (Group) Inc(000661) .
From the perspective of the China EU medical and health mixed fund managed by Glenn, the top ten heavyweight stocks at the end of the third quarter of last year have all fallen by more than 5% since the beginning of the year; In the past month, 7 fell by more than 10%, while Aier Eye Hospital Group Co.Ltd(300015) , Asymchem Laboratories (Tianjin) Co.Ltd(002821) , Pharmaron Beijing Co.Ltd(300759) , Topchoice Medical Co.Inc(600763) , Chongqing Zhifei Biological Products Co.Ltd(300122) 5 fell by more than 17%; Since the end of the third quarter of last year, all have fallen by more than 10%, and six have fallen by more than 30%.
Although the products managed by Glenn have not disclosed the fourth quarter report of 2021, it can also be seen from its fund net value. According to the data of Tiantian fund, on January 19, the net value of China EU medical and health hybrid a managed by Glenn fell by 2.68%, and the net value of China EU medical innovation stock a fell by 3.15%. In the past month, the two funds fell by 10.47% and 11.32% respectively, and both fell by more than 20% in the past three months.
Image source:
In the face of the sharp decline in the net value of the “medical goddess” managed fund, Jimin also showed a different attitude in the comment area. Some Jimin think that if they fall so much, they have to continue to increase their positions; However, some Jimin said that they have been adding positions every time they fall, and light positions have become heavy positions, which can’t be added.
Image source:
is the pharmaceutical sector ready for layout?
Can the continuously adjusted pharmaceutical sector usher in “spring” in 2022? How to capture opportunities in the pharmaceutical field?
Mingshi Partnership Fund believes that under the background of medical insurance fee control, centralized purchase has become a normal action. Within the previous valuation framework, the enterprises involved generally adopt the valuation method of discounting the forward market value. The forward market capitalization discount should consider both the impact of profitability and the impact of return. The sharp price reduction of centralized purchase will not only improve the penetration of products in the short term, but also affect the potential market value.
Roughly speaking, assuming that the price of products is reduced by 50%, and the long-term penetration and market share of the company remain unchanged, the future market scale will also be reduced by 50%. With the change of capital market environment, the required rate of return for enterprises is also increasing. These enterprises experienced the process of killing both long-term performance and valuation, and the stock price fell firmly.
However, Mingshi Partnership Fund believes that everything should also have two sides. At present, the market is panic about the companies involved in centralized purchase, but what the fund manager needs to do is to recalculate the long-term space and look for buying points that can provide sufficient safety margin. When the impact of centralized purchase is fully reflected in the stock price, it will become a good layout opportunity.
Liu Hua, partner, research director and investment manager of Dapu assets, said that new blue chips such as medicine and consumption may not usher in “spring” as a whole in 2022, and it is necessary to judge each subdivided field in detail. In medicine, the impact of centralized purchase policy on the pharmaceutical industry exists for a long time. Some subdivided fields that have just entered the scope of centralized purchase, such as instruments and insulin, or biological drugs and diagnostic reagents that are speculated to enter the scope of centralized purchase, can be avoided; For the subdivided fields that have been in the scope of centralized purchase for many years and have been relatively stable in terms of pattern, price and valuation digestion, such as some innovative drugs and generic drugs, the allocation can be reconsidered; There are also some subdivided fields that are not affected by centralized purchase, which can be considered for configuration.
150000 shareholders even “eat” 2 fell by the limit of 19.4 billion, the market value evaporated, and the per capita floating loss was 130000 yuan! Netizens want to cry without tears. What happened to the 100 billion “medical leader”?
